Novel BPA Formulation

About Ten Boron

Tenboron is a Finnish biotech pioneering next-generation carriers for Boron Neutron Capture Therapy (BNCT), a targeted radiotherapy. The company is advancing a clinical-stage pipeline led by TB0010, an antibody-boron conjugate for recurrent head and neck cancer, with Phase 1b trials on the horizon. Founded in 2010, it leverages a seasoned leadership team with deep experience in oncology drug development and BNCT. Tenboron operates as a private, pre-revenue entity, relying on partnerships for manufacturing and clinical research.

Therapeutic Areas